TP53 R249

与野生型突变株相比，这种突变株对阿霉素治疗反应更灵敏。虽然个体TP53突变的预后影响受所研究队列的影响，但有人认为，与野生型相比，R249突变与乳腺癌患者更差的总生存率相关。
This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R249 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.